14:41 , Mar 7, 2019 |  BC Innovations  |  Translation in Brief

Blocking B cell vesicles to enhance chemotherapy

Blocking extracellular vesicles derived from B cells could offer a new therapeutic avenue to enhance the efficacy of chemotherapy for cancer, according to a Zhejiang University study. Chemotherapy reduces antitumor immunity by inducing systemic immunosuppression....
15:49 , Feb 28, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Patient sample and mouse studies suggest inhibiting RAB27A-dependent formation of CD19-positive extracellular vesicles could enhance the efficacy of chemotherapy for colorectal cancer. In serum samples from colorectal cancer patients, levels of CD19-positive...
21:06 , Dec 14, 2018 |  BC Week In Review  |  Clinical News

Adcetris improves PFS by 27.4 months in first-line PTCL

Seattle Genetics Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) reported detailed data from the Phase III ECHELON-2 trial to treat previously untreated CD30-expressing peripheral T cell lymphoma (PTCL) showing that Adcetris brentuximab vedotin plus...
20:34 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Adcetris meets in Phase III for first-line PTCL

Seattle Genetics Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said Adcetris brentuximab vedotin plus chemotherapy met the primary and all key secondary endpoints in the Phase III ECHELON-2 trial to treat previously untreated CD30-expressing...
17:38 , Sep 28, 2018 |  BC Week In Review  |  Clinical News

Cell Medica doses first neuroblastoma patient with NK cell therapy

Cell Medica Ltd. (London, U.K.) dosed the first patient in the open-label, U.S. Phase I GINAKIT2 trial of CMD-501 to treat relapsed or refractory pediatric neuroblastoma, which the company said marks the first use of...
18:40 , Aug 8, 2018 |  BC Innovations  |  Emerging Company Profile

Catching antibodies with polymers

Polyneuron Pharmaceuticals AG's glycopolymers act as decoys for the autoantibodies that drive autoimmune diseases, such as anti-MAG neuropathy, and are designed to be more effective and safer than other therapies. Polyneuron's Antibody-Catch platform generates glycopolymers...
16:43 , Jul 6, 2018 |  BC Week In Review  |  Clinical News

Spectrum's Rolontis meets in second Phase III for chemotherapy-induced neutropenia

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) said Rolontis eflapegrastim met the primary endpoint of non-inferiority to Neulasta pegfilgrastim in the Phase III RECOVER trial in 237 early stage breast cancer patients who received docetaxel and cyclophosphamide every...
20:35 , Jun 6, 2018 |  BC Innovations  |  Translation in Brief

Distinguishing DLBCL

A genomics-based method of subtyping diffuse large B cell lymphoma could improve prognostic predictions and identification of subtype-appropriate treatment regimens. Diffuse large B cell lymphoma (DLBCL) is clinically and genetically heterogeneous and roughly 40% of...
18:30 , Apr 20, 2018 |  Clinical Results  |  Clinical Results

BriaCell's Bria-IMT leads to tumor regressions in Phase I/IIa for breast cancer

BriaCell Therapeutics Corp. (TSX-V:BCT; OTCQB:BCTXF) reported data from six patients with stage IV breast cancer in the Phase I/IIa WRI-GEV-007 trial showing that Bria-IMT (SV-BR-1-GM) led to tumor regression in two patients, including one with...
17:45 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

Northwestern researchers report Phase III MS data for HSCT vs. continuing disease-modifying therapies

Researchers at Northwestern University and colleagues reported data from a Phase III trial in 110 patients with highly active relapsing-remitting multiple sclerosis (MS) showing that conditioning with cyclophosphamide and rabbit anti-thymocyte globulin followed by non-myeloablative...